Vyndamax
Chemical Name | tafamidis |
Dosage Form | Capsule (oral; 61 mg) |
Drug Class | Inhibitors |
System | Cardiovascular |
Company | Pfizer |
Approval Year | 2019 |
Indication
- For the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization